Pancreatic cancer research explores early detection biomarkers, stromal targeting, KRAS-directed therapy, and neoadjuvant treatment approaches.
A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.
The Step 2 randomization of NRG Oncology/RTOG 0848, a phase III trial of 354 patients with resected pancreatic head adenocarcinoma, found that adding chemoradiotherapy (CXRT) to adjuvant chemotherapy did not significantly improve overall survival across the full study population.
Paired ctDNA profiling of 44 patients with RAS-mutant metastatic pancreatic cancer who progressed on daraxonrasib monotherapy found acquired RAS pathway alterations in 26 of 44 patients (59%), with mutant KRAS amplification the dominant mechanism (36%, 16 of 44).
Open-label, single-arm phase 1b/2 trial of HRS-4642 — an intravenous, liposomal-nanoparticle KRAS-G12D inhibitor — added to gemcitabine and nab-paclitaxel (the "AG" backbone) in advanced KRAS-G12D-mutant pancreatic ductal adenocarcinoma (PDAC); 68 patients screened, 31 treated, 30 treatment-naive